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intRODUctiOn
Parkinson’s disease (PD) is a neurodegenerative disorder secondary to the progressive loss 
of dopaminergic neurons in the substantia nigra (a portion of the midbrain responsible for 
movement initiation and coordination) and appearance of bradykinesia, resting tremor, ri-
gidity and postural reflex impairment. The most common symptomatic therapy is levodopa, 
a dopamine precursor; however, long-term treatment leads to involuntary movements and 
response fluctuations which add to the complexities of later disease-management. Mo-
notherapy with dopamine agonists may represent an alternative approach with a reduced 
likelihood of motor complications; these drugs, initially introduced as adjunctive therapy 
to levodopa, are less effective in controlling motor disability and tend to cause more side 
effects than levodopa itself.
inDicatiOnS anD DOSinG
Rotigotine is a new chemical substance belonging to the group of non-ergolinic dopamine 
agonists. This drug is used for the treatment of early-stage Parkinson disease as monotherapy, or 
with levodopa at all stages of the disease. The drug is available in transdermal patches of several 
sizes, containing different doses of rotigotine (Table I).
 Recently, the Committee for Medicinal Products for Human Use (CHMP) of the EMEA issued 
a positive opinion on marketing authorization for rotigotine for idiopathic Restless Legs Syndro-
me (RLS) treatment. Rotigotine is currently included by AIFA (Agenzia Italiana del Farmaco) in 
a drug efficacy and safety monitoring program.
In early PD, the starting dose is 2mg/24h (4mg/24h  for advanced PD), increased every week 
by 2mg/24h until an effective dose is reached, or  up to a maximum dose of 8mg/24h (16mg/24h 
for advanced PD). 
Size 10 cm2 20 cm2 30 cm2 40 cm2
Dose contained (mg) 4.5 9.0 13.5 18.0
Dose released (mg) 2 4 6 8
Table I
All available presentations for rotigotine transdermal application
PhaRmacOkineticS
The drug in the patch is constantly and dose-proportionately released over 24-h, resulting in 
constant plasmatic concentrations with daily application. The absorption of rotigotine is not in-
fluenced by gender, age, race, impaired renal or hepatic function. Rotigotine is widely distribu-
ted into tissues and extensively metabolized; the drug and its metabolites are mainly excreted in 
urine and less in bile and stool.
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Absorption Bioavailability* High variability (1- 64%), mean 37%
Cmax 7 ng/ml after 1mg/Kg administration
Tmax 15-18 h (1- 27 h)
Binding to plasma proteins 90.5-92.7%
Metabolism and 
distribution
Volume of distribution 84 l/kg
Metabolism Dealkyilation/ monoidroxilation, conjugation with glucuronic or sulphate acid
Enzimes CYP450: CYP2C19 
Several sulphotransferases and UDP-glucorosyltransferases
Biological activity of metabolites Not present
Elimination Clearance 630 l/h
Plasma terminal half-life 5-7 h
Elimination 71% urine, 23% bile and faeces
Interactions No interactions
Table II
Absorption, distribution, metabolism and elimination of rotigotine after transdermal administration
FaRmacODynamicS
Rotigotine acts like a typical dopamine-agonist: this drug shows a close structural and func-
tional analogy to dopamine, with a similar receptor binding and functional profile. Rotigotine is 
an agonist at all dopamine receptors, showing highest affinity and activity via the D3 receptor 
(the most widely cited receptor in the inhibition of locomotor activity).
eFFicacy anD SaFety 
The clinical development program for the rotigotine patch comprised four main studies (Phase 
III trials ): SP512 and SP513 to evaluate rotigotine efficacy in monotherapy in early-stage idiopathic 
PD; SP650 and SP515 to evaluate rotigotine efficacy in combination with levodopa in advanced 
idiopathic PD. SP512 and SP650 trials were placebo-controlled, whereas SP513 and SP515 were 
controlled against another dopamine agonist (ropinirole and pramipexole, respectively). 
The primary efficacy end-point for monotherapy trials was based upon the UPDRS II/III score 
(Unified Parkinson’s disease rating scale, a compilation of various PD assessment scales, the most 
frequently used for evaluating treatment responses), whereas  for the evaluation of rotigotine in 
combination with levodopa the primary variable was the change in absolute time spent “off” (time 
during which PD symptoms are most prominent). 
The safety profile of rotigotine can be considered typical of a dopamine-agonistic agent, with 
adverse reactions (AEs) like nausea, somnolence, vomiting, fatigue and constipation; the only 
exception is the high frequency of skin reactions in the application site. An increased frequency 
of AEs was observed in adjuvant therapy with levodopa, as compared to monotherapy.
Study Design Comparator Efficacy Safety
Monotherapy
SP512 277 pts with early PD 
randomized 1:1
Double-blind, multi center, 
placebo-controlled 
Placebo 20% Improvement
P: 19% pts
Rt: 48% pts (p < 0.0001)
Change in UPDRS II/III* score
P: 1.31
Rt: -3.98 (p < 0.0001)
AEs ≥ 5% subjects: 
P: 57% pz
Rt: 76% pz
Rp: 70% pz
AEs typical of a dopamine agonist, 
with an higher frequency of skin 
reaction in the application site  
(P = 14%, Rt = 37%, Rp = 8%) 
SP513 561 pts with early PD 
randomized 1:1:1
Double-blind, multi center, 
placebo-controlled, active 
treatment 
Placebo, 
ropinirole 
20% Improvement
P: 30% pts
Rt: 52% pts (p < 0.0001)
Rp: 70% pts (p < 0.0001)
Change in UPDRS II/III* score
P: - 2.33
Rt: -6.83 
Rp: -10.78
Not showed non-inferiority to Rp 
Continued next page >
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Study Design Comparator Efficacy Safety
Adjoint to levodopa
SP650 351 pts with advanced PD 
(≥ 2.5 h “OFF”/day) non 
adequately controlled by 
levodopa,  randomized 1:1:1
Double-blind, placebo-
controlled
Placebo Reduction in “off” time ≥ 30%
P: 34.5%
Rt 18mg: 56.6% (p < 0.001)
Rt 27mg: 55.1% (p < 0.001)
Change in “off” time (hrs)
P: 0.9
Rt 18mg: 2.7 (p < 0.001)
Rt 27mg: 2.1 (p = 0.003)
AEs ≥ 5% subjects: 
P: 62.6% pz
Rt: 73.0% pz
Rp: 70.3 % pz
AEs typical of a dopamine agonist, 
with an higher frequency of skin 
reaction in the application site  
(P: 20.1%, Rt: 39.9%, Pr: 11.9%)
SP515 506 pts with advanced PD 
(≥ 2.5 h “OFF”/day) non 
adequately controlled by 
levodopa, randomized 2:2:1  
Double-blind, placebo-
controlled.
Placebo, 
pramipexole
Reduction in “off” time ≥ 30%
Pr: 35%
Rt: 59.7% (p < 0.001)
P: 67% (p < 0.001)
Change in “off” time (hrs)
P: 0.88
Rt: 2.46 (p < 0.0001)
Pr: 2.81 (p < 0.0001)
Showed non-inferiority to Pr
Table III
Summary of main studies investigating efficacy and safety of rotigotine monotherapy for early PD (SP512, versus placebo; SP513, 
versus placebo and ropinirole) or for advanced PD, in combination with levodopa (SP650, versus placebo; SP515, versus placebo and 
pramipexole)
* UPDRS score (Unified Parkinson’s disease rating scale) in part II (daily activities) and III (motor evaluations) of questionnaire is the primary 
efficacy end-point for monotherapy trials; maximum score is 160 (52 + 108) points (worst scenario) and the absence of disease signs 
is associated with a 0 score
 AEs = adverse events ; P = placebo; Pr = pramipexole; Rp = ropinirole; Rt = rotigotine
ecOnOmic evaLUatiOnS
We were not able to retrieve any published economic evaluation on the use of rotigotine in Parkinson disease.
In table IV we calculated monthly pharmaceutical costs for available therapies for PD treatment. For each formulation 
we valorized minimum and maximum dosing (from the Summary Product Characteristics - SPCs) and DDD (Defined Daily 
Dose) for one month of therapy, using retail price. For packages with identical price we considered the less costly one. This 
is not to be intended as a cost-minimization analysis, but as a simple overlook of currently available treatments. 
Drug and dosing range Reimbursed 
price
/ package
Price of therapy (1 month)
Category Active principle (DDD) < > DDD
Anticholinergics biperidene (10 mg ) 2 mg 4.29 3.2175 21.45 10.725
4 mg 5.33 3.198 9.594 7.995
5 mg 2.94 35.28 70.56 35.28
Antihistaminics orfenadrine (200 mg) 50 mg 2.12 2.544 10.176 5.088
Levodopa and derivates levodopa + benserazide (600 mg) 100+25 mg 4.71 - - 28.26
200+50 mg 16.84 - - 30.312
s.r. 100+25 mg 5.56 - - 33.36
levodopa + carbidopa (600 mg) 100+25 mg 4.98 8.964 23.904 17.928
250+25 mg 6.68 2.004 32.064 9.6192
s.r. 100+25 mg 8.12 9.744 43.848 29.232
s.r. 200+50 mg 9.93 19.86 79.44 29.79
m.r. 100+25 mg 9.21 11.052 44.208 33.156
m.r. 200+50 mg 11.01 22.02 33.03 33.03
melevodopa + carbidopa (600 mg) 100 mg 9.12 27.36 54.72 54.72
125 mg 9.12 9.12 54.72 43.776
250 mg 9.12 9.12 54.72 21.888
Continued next page >
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Drug and dosing range Reimbursed 
price
/ package
Price of therapy (1 month)
Category Active principle (DDD) < > DDD
Admantane derivates amantadine (200 mg)* 100 mg 7.1 10.65 21.3 21.3
Dopamine agonists  
non ergot derived
apomorphine 30 mg 21.67 65.01 650.1 -
50 mg** 39.402268 118.2 472.8 -
rotigotine (6 mg) 2 mg 96.04 102.9 102.9 308.7
4 mg 100.36 107.5286 107.5286 161.2929
6 mg 130.47 139.7893 139.7893 139.7893
8 mg 160.56 172.0286 172.0286 129.0214
ropinirole (6 mg) 0.25 mg 4.75 40.71429 244.2857 162.8571
0.5 mg 8.68 37.2 223.2 148.8
1 mg 10.44 22.37143 134.2286 89.48571
2 mg 20.82 29.74286 118.9714 89.22857
5 mg 44.04 31.45714 125.8286 75.49714
pramipexole (2.5 mg) 0.25 mg 16.52 33.04 297.36 165.2
1 mg 65.16 65.16 293.22 162.9
Dopamine agonists  
ergot derived
cabergoline (3 mg) 1 mg 19.16 28.74 172.44 86.22
2 mg 38.02 28.515 171.09 85.545
bromocriptine (40 mg) 5 mg 11.53 11.53 46.12 92.24
10 mg 14.66 10.995 43.98 87.96
pergolide (3 mg) 0.05 mg 8.63 8.63 172.6 517.8
0.25 mg 16.48 12.36 247.2 148.32
1 mg 18.2 27.3 136.5 81.9
dihydroergocryptine (60 mg)* 20 mg 34.88 26.16 313.92 156.96
MAO B inhibitors selegiline (5 mg)* 1.25 mg 40.56 40.56 40.56 162.24
5 mg 17.04 10.224 20.448 10.224
10 mg 18.36 11.016 22.032 11.016
rasagiline (1 mg) 1 mg 135.55 145.2321 145.2321 145.2321
Other dopaminergic 
substances 
tolcapone (450 mg) 100 mg 165.33 148.797 297.594 223.1955
entacapone (1 g) 200 mg 116.02 34.806 348.06 174.03
Table IV
Monthly pharmaceutical costs for different available therapies for PD treatment (Informatore Farmaceutico 2008)
* Not in the Italian reimbursement list; **Ex-factory price
PRODUct OveRvieW
name of the medicinal Product Neupro 
marketing authorisation holder SCHWARZ PHARMA Ltd 
active Substance Rotigotine
Pharmaco-therapeutic Group Dopamine agonist 
atc code N04BC09 
Date of issue of marketing authorisation valid throughout the european Union 15 February 2006  
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